Immunotherapy/BCG Combo Boosts EFS in Non-Muscle Invasive Bladder Cancer
LAS VEGAS — Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus Calmette-Guérin (BCG), a randomized trial showed. The 3-year EFS increased from 74.8% with standard-of-care BCG induction and maintenance to 82.1% with the addition of sasanlimab. Most of the improvement […]
Unprecedented Response Rates in Non-Responsive, Non-Muscle Invasive Bladder Cancer
LAS VEGAS — Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational intravesical treatment system, data from an ongoing trial showed. Complete responses (CR) occurred in 82.4% of 85 patients treated with TAR-200, a system that delivers gemcitabine directly into the bladder. The […]